SymBio Pharmaceuticals Limited

OTCPK:SYMQ.Y Stock Report

Market Cap: US$41.4m

SymBio Pharmaceuticals Management

Management criteria checks 2/4

SymBio Pharmaceuticals' CEO is Fuminori Yoshida, appointed in Mar 2005, has a tenure of 21.08 years. directly owns 2.35% of the company’s shares, worth $970.48K. The average tenure of the management team and the board of directors is 2.2 years and 4.6 years respectively.

Key information

Fuminori Yoshida

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure21.1yrs
CEO ownership2.3%
Management average tenure2.2yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

CEO

Fuminori Yoshida (76 yo)

21.1yrs
Tenure

Mr. Fuminori Yoshida serves as President, Chief Executive Officer and Chief Operating Officer of Takeda Bio Development Center Limited. Mr. Yoshida founded SymBio Pharmaceuticals Limited in March 2005 and...

Leadership Team

NamePositionTenureCompensationOwnership
Fuminori Yoshida
CEO, President & Representative Director21.1yrsno data2.35%
$ 970.5k
Takeo Okuno
Corporate Officer & CFO1.3yrsno datano data
Yoshiharu Torikai
Corporate Officerno datano datano data
Masahiko Okuno
Corporate Officer3.1yrsno datano data
Hiroyuki Horita
Corporate Officer3.3yrsno datano data
Edwin Rock
Corporate Officerless than a yearno datano data
Minori Rosales
Corporate Officerless than a yearno datano data
2.2yrs
Average Tenure
63yo
Average Age

Experienced Management: SYMQ.Y's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Fuminori Yoshida
CEO, President & Representative Director21.1yrsno data2.35%
$ 970.5k
George Morstyn
Independent Outside Director2.1yrsno datano data
Robert Lewis
Member of Scientific Advisory Boardno datano datano data
Tsutomu Takeuchi
Member of Scientific Advisory Boardno datano datano data
Toshio Suda
Member of Scientific Advisory Boardno datano datano data
Tatsutoshi Nakahata
Member of Scientific Advisory Boardno datano datano data
Makoto Ogawa
Member of Scientific Advisory Boardno datano datano data
Toshio Heike
Member of Scientific Advisory Boardno datano datano data
Shinji Nakao
Member of Scientific Advisory Boardno datano datano data
Ralph Smalling
Outside Independent Director1.1yrsno datano data
Koichi Shimomura
Outside Independent Directorno datano datano data
Bruce David Cheson
Independent Outside Director7.1yrsno datano data
4.6yrs
Average Tenure
75yo
Average Age

Experienced Board: SYMQ.Y's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/29 13:17
End of Day Share Price 2026/01/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SymBio Pharmaceuticals Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathaniel CallowayEdison Investment Research
Kiyokazu YamazakiIchiyoshi Research Institute Inc.